European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
p53 expression in ovarian carcinoma with regard to second-look findings
Forty-eight (48) cases of ovarian carcinoma subjected to primary surgery and platinum based chemotherapy followed by secondlook laparotomy (SLL) were analyzed with respect to p53 status. Overall aberrant p53 accumulation was observed in 20 (41.6%) out of 48 patients. While one out of 5 patients (20.0%) with stage 1-11 disease showed positive p53 staining, 19 out of 43 patients (44.1 %) with stage III disease were found to be positive for p53. According to the histologic types, 41.9% of serous (13/31), 33.3% of endometrioid (2/6), 50.0% of transitional (2/4), 40.0% of mixed (2/5) and 50,0% of mucinous types of tumors showed abnormal expression of p53. p53 positivity was found in 12 (54.5%) out of 22 SLL (+) patients while only 8 (30.7%) were p53 positive out of 26 with SLL (-) patients. Cases with abnormal p53 accumulation tended to be SLL positive, however, the difference was not significant.